NCT07256431 2025-12-01
RIS - EBVD
Centre Hospitalier Universitaire de Nīmes
Completed
Clinical Trials
54 trialsNCT04189835 2025-11-20
EVITA
University of Aarhus
Completed
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02580539 2025-05-14
EBV-TCL-01
Maisonneuve-Rosemont Hospital
Phase 1/2 Completed
NCT05815108 2025-05-08
EBV-RIS
Centre Hospitalier Universitaire de Nice
Completed
NCT04693637 2024-05-09
Prevent
AlloVir
Phase 2/3 Completed
NCT06002802 2024-02-07
IMMUC
Technical University of Munich
Completed
NCT03546101 2023-10-31
Early Detection of Epstein-Barr Virus Related Disease.
University of Aarhus
Completed
NCT00834093 2023-06-28
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02578641 2023-06-28
VANCE
Tessa Therapeutics
Phase 3 Completed
NCT03374566 2023-02-09
Immunodeficiency for Severe Epstein-Barr Virus Infection
Children's Hospital of Fudan University
Completed
NCT05604378 2022-11-03
Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis
Saint Vincent's Hospital, Korea
Completed
NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT02496676 2022-03-02
Magnesium Supplementation in People With XMEN Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02499302 2022-02-16
Mental Training for CFS Following EBV Infection in Adolescents
University Hospital, Akershus
Phase NA Completed
NCT00000712 2021-11-04
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT01535885 2021-10-25
ACE
Medical College of Wisconsin
Phase 1 Completed
NCT01094405 2021-07-28
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Chinese University of Hong Kong
Phase 2 Completed
NCT02108522 2021-07-20
CHARMS
AlloVir
Phase NA Completed
NCT02227641 2020-12-14
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
University of Erlangen-Nürnberg Medical School
Phase 1/2 Completed
NCT00342147 2020-12-11
Family Study of Head and Neck Cancers in Taiwan
National Institutes of Health Clinical Center (CC)
Completed
NCT00267865 2020-06-01
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01196520 2020-05-22
Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
National Institutes of Health Clinical Center (CC)
Completed
NCT00058591 2020-01-18
SCAEBV
Baylor College of Medicine
Phase 1 Completed
NCT02000817 2019-06-24
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
GlaxoSmithKline
Phase 1/2 Completed
NCT03981224 2019-06-10
The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients
Taichung Veterans General Hospital
Completed
NCT01570283 2019-05-30
ARMS
AlloVir
Phase 1/2 Completed
NCT03378947 2019-02-22
EBV-associated Diffuse Large B Cell Lymphoma
Hospices Civils de Lyon
Completed
NCT02269943 2018-12-12
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
Phase 2 Completed
NCT03650231 2018-08-28
DIAGEPS
Centre Hospitalier Universitaire, Amiens
Completed
NCT01800071 2018-07-17
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
Cancer Research UK
Phase 1 Completed
NCT01058239 2018-02-15
Bortezomib Plus Rituximab for EBV+ PTLD
Massachusetts General Hospital
Phase 2 Completed
NCT00953420 2017-08-18
CADEN
Baylor College of Medicine
Phase 2 Completed
NCT00001156 2017-07-02
Assessment of Patients With Multiple Sclerosis (MS)
National Institutes of Health Clinical Center (CC)
Completed
NCT00005924 2017-07-02
Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus
National Institutes of Health Clinical Center (CC)
Completed
NCT00359411 2017-07-02
Genetic Studies of X-linked Lymphoproliferative Disease
National Institutes of Health Clinical Center (CC)
Completed
NCT02335437 2017-06-28
CEBA
University Hospital, Akershus
Completed
NCT00711035 2016-04-26
CHALLAH
Baylor College of Medicine
Phase 1/2 Completed
NCT02715752 2016-04-26
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
The Center for the Biology of Chronic Disease
Completed
NCT02630537 2015-12-15
Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients
Lophius Biosciences GmbH
Completed
NCT00706316 2015-07-10
NPC-CTL
University Health Network, Toronto
Phase 1 Completed
NCT00963248 2015-04-13
EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
Klinik für Kinder- und Jugendmedizin
Completed
NCT00058812 2015-01-29
ETNA
Baylor College of Medicine
Phase 1 Completed
NCT01070797 2014-09-04
VIRAGE
Baylor College of Medicine
Phase 1 Completed
NCT00078546 2012-07-30
CLANC
Baylor College of Medicine
Phase 1 Completed
NCT00779337 2012-05-22
EPL
Queensland Institute of Medical Research
Phase 1 Completed
NCT01147991 2012-02-28
Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
Cancer Research UK
Phase 1 Completed
NCT00701922 2011-10-28
Surveillance Study of Viral Infections Following Lung Transplantation
Hannover Medical School
Completed
NCT00274404 2011-10-27
Controlled Trial of Valacyclovir in Infectious Mononucleosis
University of Minnesota
Phase 1/2 Completed